Thromboembolism in patients with melanoma receiving immune checkpoint inhibitors: incidence and risk factors

Thromboembolism in patients with melanoma receiving immune checkpoint inhibitors: incidence and risk factors

Background: Immune checkpoint inhibitors (ICIs) may increase the incidence of thromboembolisms (TEs). In patients with melanoma, the risk of TE and its association with the disease setting remains largely unknown. This study investigated the incidences of arterial thromboembolism (ATE) and venous th...

Full description

Saved in:
Bibliographic Details
Main Authors: D.C.H. van Dorst, M.M. Hofman, R.M. de Waal, E. Oomen-de Hoop, K. de Joode, S. Bins, S.L.W. Koolen, A. Joosse, J. Versmissen, M.J.H.A. Kruip, A.A.M. van der Veldt, R.H.J. Mathijssen
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:Immuno-Oncology and Technology
Subjects:
melanoma
immune checkpoint inhibitors
thromboembolism
arterial thromboembolism
venous thromboembolism
side-effects
Online Access:http://www.sciencedirect.com/science/article/pii/S2590018825000231
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2590018825000231

Similar Items